Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
Ritchie AJ. et al, (2025), Vaccine, 47
A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies novel host-pathogen interactions.
Segireddy RR. et al, (2024), Malaria journal, 23
Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response.
Joe CCD. et al, (2023), Biotechnol Bioeng
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Measurement of Adenovirus-Based Vector Heterogeneity.
Hickey JM. et al, (2023), Journal of pharmaceutical sciences, 112, 974 - 984
Rapid-response manufacturing of adenovirus-vectored vaccines
Joe CCD. et al, (2023), Nature Biotechnology
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671
STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.
Padron-Regalado E. et al, (2022), Scientific reports, 12
Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies.
Ng WM. et al, (2022), Cell host & microbe
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58
Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Dulal P. et al, (2021), Scientific reports, 11
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire
Swanson PA. et al, (2021), Science Translational Medicine, 13
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040
Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations.
Berg A. et al, (2021), Vaccines, 9
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Dulal P. et al, (2021), Scientific reports, 11
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113